Date: 2015-05-19
Type of information: Initiation of the trial
phase: 2
Announcement: initiation of the trial
Company: Eli Lilly (USA - IN)
Product: prexasertib (LY2606368)
Action
mechanism: checkpoint kinase inhibitor. Prexasertib is an inhibitor of checkpoint kinase 1 (chk1) with potential antineoplastic activity. Upon administration, prexasertib selectively binds to chk1, thereby preventing activity of chk1 and abrogating the repair of damaged DNA. This may lead to an accumulation of damaged DNA and may promote genomic instability and apoptosis. Prexasertib may potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapeutic agents. Chk1, a serine/threonine kinase, mediates cell cycle checkpoint control and is essential for DNA repair and plays a key role in resistance to chemotherapeutic agents.
Disease: small cell lung cancer
Therapeutic area: Cancer - Oncology
Country: France, Germany, Greece, Korea, Republic of, Netherlands, Spain, Turkey, Ukraine, UK, USA
Trial
details: The purpose of this study is to evaluate the safety and efficacy of prexasertib (LY2606368) when given to participants with extensive stage disease small cell lung cancer (ED-SCLC). The study will evaluate how the body processes the drug and how the drug affects the body. The study will also evaluate the association between tumor response and the participant's perceived quality of life. (NCT02735980)
Latest
news: * On May 19, 2015, a Phase 2 trial sponsored by Eli Lilly was published on the NIH website ClinicalTrials.gov for prexasertib (LY2606368) and is currently recruiting participants.
